zileuton has been researched along with Cancer of Colon in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentrem, DJ; Blatner, NR; Cheon, EC; Gounaris, E; Grippo, PJ; Heiferman, JR; Heiferman, MJ; Khazaie, K; Knab, LM; Munshi, HG; Phillips, JD; Shrivastav, M; Vitello, D | 1 |
| Hussey, HJ; Tisdale, MJ | 1 |
2 other study(ies) available for zileuton and Cancer of Colon
| Article | Year |
|---|---|
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Topics: Animals; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Hydroxyurea; Inflammatory Bowel Diseases; Intestinal Polyposis; Lipoxygenase Inhibitors; Male; Mice; Mice, Mutant Strains | 2015 |
Inhibition of tumour growth by lipoxygenase inhibitors.
Topics: Adenocarcinoma; Administration, Oral; Analysis of Variance; Animals; Benzeneacetamides; Cell Division; Colonic Neoplasms; Hydroxamic Acids; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mice; Neoplasm Transplantation; Treatment Outcome; Tumor Cells, Cultured | 1996 |